Table 1 Patient characteristics and response outcomes.
Characteristics | All patients (n = 38) |
|---|---|
Age | |
Median (range)—yr | 68(41–81) |
≥75 yr—no. (%) | 11(28.9) |
Gender—no. (%) | |
Male | 22(57.9) |
Female | 16(42.1) |
ECOG performance-status score — no. (%)λ | |
0–1 | 21(55.3) |
2–3 | 17(44.7) |
Bone marrow blast count — no. (%) | |
<30%‡ | 3(8.1) |
≥30 to <50% | 13(35.1) |
≥50% | 21(56.8) |
Missing | 1(2.6) |
WBC count (range) — x 109/L | 9.9 (0.9-184.7) |
Platelet count (range) — x 109/L | 42(3-180) |
Selected molecular mutation — no. (%) | |
TP53 | 1(2.6) |
FLT3-ITD | 4(10.5) |
NPM1 | 7(18.4) |
IDH1/2 | 10(26.3) |
ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 | 10(26.3) |
CEBPA (bZIP in-frame) | 4(10.5) |
Missing | 3(7.9) |
ELN-2022 risk classification — no. (%) | |
Favorable | 14(36.8) |
Intermediate | 10(26.3) |
Adverse | 11(28.9) |
Missing | 3(7.9) |
Response after one cycle — no. (%) | |
CR | 24(63.2) |
CRi | 7(18.4) |
60-day mortality — no. (%) | 1(2.6) |
Median PFS— months. (95% CI) | 9.0(7.9-10.1) |
Median OS— months. (95% CI) | 17.0(10.4–23.6) |
Time to blood cell count recovery¶ after induction—days. (IQR) | 29(21–37) |
Time to ANC recovery to 0.5 × 109/L— days. (IQR) | 23(14–30) |
Time to ANC recovery to 1.0 × 109/L— days. (IQR) | 26(21–34) |
Time to PLT count recovery to 20 × 109/L— days. (IQR) | 14(0-21) |
Time to PLT count recovery to 50 × 109/L— days. (IQR) | 21(16–34) |
Time to PLT count recovery to 100 × 109/L— days. (IQR) | 22(19–45) |
